Company Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities.
The company was founded in 2018 and is based in Carmel, Indiana.
| Country | United States |
| IPO Date | Jan 14, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Peter Kent Hawryluk MBA |
Contact Details
Address: 11711 N. Meridian Street Carmel, Indiana United States | |
| Website | https://mbxbio.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US55287L1017 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Peter Kent Hawryluk MBA | Chief Executive Officer, President & Director |
| Richard B. Bartram CPA | Chief Financial Officer |
| Dr. Salomon Azoulay | Chief Medical Officer |
| Dr. Steven J. Prestrelski M.B.A., MBA, Ph.D. | Chief Scientific Officer |
| Matt Gambino | Vice President of Marketing |
| Michelle Graham | Chief Human Resources Officer |